Dr. Lal PathLabs (NSE:LALPATHLAB) EBIT : ₹5,943 Mil (TTM As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Dr. Lal PathLabs EBIT?

Dr. Lal PathLabs's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ₹1,891 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹5,943 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Dr. Lal PathLabs's annualized ROC % for the quarter that ended in Sep. 2024 was 32.00%. Dr. Lal PathLabs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 229.84%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Dr. Lal PathLabs's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 2.64%.

Dr. Lal PathLabs EBIT Historical Data

The historical data trend for Dr. Lal PathLabs's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr. Lal PathLabs EBIT Chart

Dr. Lal PathLabs Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT

Get a 7-Day Free Trial

3,258.15

4,104.12

5,051.00

3,813.60

5,348.10

Dr. Lal PathLabs Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															1,600.00	1,229.00	1,264.10	1,559.00	1,891.00

Competitive Comparison of Dr. Lal PathLabs's EBIT

For the Diagnostics & Research subindustry, Dr. Lal PathLabs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dr. Lal PathLabs's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dr. Lal PathLabs's EV-to-EBIT falls into.

Dr. Lal PathLabs EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹5,943 Mil.

Dr. Lal PathLabs (NSE:LALPATHLAB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Dr. Lal PathLabs's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	6688 * ( 1 - 28.56% )	/	( (0	+	14932)	/ 1 )
=	4777.9072	/	14932
=	32.00 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	25975	-	2411	-	( 11607	-	max(0, 4624	-	13256	+	11607	))
=	14932

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Dr. Lal PathLabs's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	7564	/	( ( (0 + max(0, 0))	+	(3291 + max(-1968, 0)) )	/	1 )
=	7564	/	( ( 0	+	3291 )	/	1 )
=	7564	/	3291
=	229.84 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(901	+	468	+	270)	-	(2411	+	0	+	1196)
=	-1968

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Dr. Lal PathLabs's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	5943.1	/	224931.507
	=	2.64 %

Dr. Lal PathLabs EBIT Related Terms

Thank you for viewing the detailed overview of Dr. Lal PathLabs's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr. Lal PathLabs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

539524:India

Address

12th Floor, Tower B, SAS Tower, Sector 38, Medicity, Gurugram, HR, IND, 122 001

Website

https://www.lalpathlabs.com

Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the area of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist to prevent, monitor and treat diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.

Dr. Lal PathLabs Headlines

No Headlines